By Billy Candra 
A groundbreaking study from the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has resolved a long-standing mystery in cancer immunology, revealing that regulatory T (Treg) cells, often viewed as detrimental "brakes" on the immune system, play a surprisingly complex and sometimes beneficial role in colorectal cancer. Published in the prestigious scientific journal Immunity, the research identifies two distinct subtypes of Treg cells with opposing effects on tumor growth, a discovery poised to revolutionize immunotherapy for the vast majority of colorectal cancer patients and potentially other solid tumors.
For decades, the scientific community has understood that a high presence of Treg cells in most solid tumors is generally associated with poorer patient outcomes. These immune suppressors typically dampen the body’s natural anti-cancer defenses, allowing malignancies to evade immune surveillance and proliferate unchecked. Colorectal cancer, however, stood as a perplexing exception to this rule. In this specific disease, higher numbers of Treg cells within tumors were, counter-intuitively, linked to longer patient survival. This anomaly had baffled researchers, preventing a clear understanding of Treg cell dynamics in one of the most common and deadly cancers worldwide.
Unraveling the Colorectal Cancer Enigma
Colorectal cancer (CRC) remains a significant global health challenge, ranking as the second leading cause of cancer-related death when men and women are counted together, according to the American Cancer Society. Each year, hundreds of thousands are diagnosed with this disease, and while treatment modalities have advanced, improving outcomes for all patients, particularly those with advanced or unresponsive tumors, remains a critical goal.
The current study, led by co-senior authors Alexander Rudensky, PhD, Chair of the Immunology Program at MSK and a Howard Hughes Medical Institute Investigator, and Christina Leslie, PhD, a computational biologist at MSK, provides the definitive explanation for this paradox. Their key finding is that the type of Treg cell, rather than simply the quantity, dictates its impact on colorectal tumors. This nuanced understanding moves beyond a simplistic "more is worse" view, opening doors for highly selective therapeutic interventions.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explained Dr. Rudensky. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
The research team included first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in Dr. Leslie’s lab, who led the extensive computational data analysis.
A Legacy of Immunological Discovery
This landmark study is built upon more than two decades of foundational research by Dr. Rudensky, recognized as one of the world’s foremost authorities on regulatory T cells. His pioneering work has been instrumental in establishing the critical role of Treg cells in maintaining "immune tolerance." This fundamental process enables the immune system to differentiate between harmful pathogens and innocuous self-components, as well as beneficial microbes and dietary elements. Without this intricate regulatory mechanism, the immune system could launch unwarranted attacks on the body’s own tissues, leading to autoimmune diseases.
Over the years, Dr. Rudensky’s lab has systematically elucidated the complex pathways governing Treg cell development, activation, and function, including their multifaceted influence on cancer progression. This deep understanding of Treg biology provided the essential framework for investigating their specific roles within the tumor microenvironment of colorectal cancer.
Focusing on the Most Common and Challenging Form of CRC
The MSK researchers strategically focused their investigation on the most prevalent form of colorectal cancer: microsatellite stable (MSS) with proficient mismatch repair (MMRp) tumors. This subtype accounts for a substantial 80% to 85% of all colorectal cancers and, critically, typically exhibits a poor response to existing checkpoint inhibitor immunotherapies.
In contrast, earlier research at MSK and elsewhere demonstrated that checkpoint inhibitors can be remarkably effective against the rarer microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) tumor type. Patients with MSI-H/dMMR CRC often achieve profound responses to immunotherapy alone, frequently enabling them to bypass conventional treatments like surgery, chemotherapy, and radiation, which carry significant side effects. The challenge, therefore, lay in improving outcomes for the majority of patients whose tumors do not benefit from these transformative immune-boosting drugs. The new study directly addresses this urgent clinical need.
The Dual Identity: IL-10 Positive and IL-10 Negative Tregs
To dissect the unique immune landscape of common colorectal cancers, the team utilized a sophisticated mouse model meticulously developed at MSK. This model faithfully recapitulates the genetic alterations, behavioral characteristics, and intricate immune microenvironment observed in human colorectal tumors, providing a robust platform for experimental manipulation and observation.
Through a series of detailed experiments, the researchers made a pivotal discovery: tumor-associated Treg cells are not a monolithic population but rather comprise two functionally distinct groups. The defining characteristic distinguishing these groups was their production of interleukin-10 (IL-10), a crucial signaling molecule or cytokine. One group actively produces IL-10, while the other does not.
By selectively removing each of these Treg groups in their mouse models, the scientists uncovered stark differences in their impact on tumor growth:
-
IL-10-Positive Treg Cells: The Protectors
- Mechanism: These cells actively slow tumor growth by reducing the activity of Th17 cells, another type of immune cell. Th17 cells produce interleukin-17 (IL-17), a cytokine known to act as a potent growth signal for tumors. By dampening Th17-mediated inflammation, IL-10-positive Tregs effectively starve the tumor of growth-promoting signals.
- Location: These beneficial Treg cells were predominantly found in the healthy tissue immediately adjacent to the tumor, suggesting a role in maintaining tissue homeostasis and preventing excessive inflammation that could otherwise fuel tumor progression.
- Experimental Evidence: When IL-10-positive Treg cells were selectively depleted from the mouse models, tumors exhibited significantly faster growth, unequivocally demonstrating their protective role.
-
IL-10-Negative Treg Cells: The Promoters of Tumor Growth
- Mechanism: In stark contrast, these cells actively suppress powerful anti-cancer immune defenders, particularly cytotoxic CD8+ T cells, which are renowned for their ability to directly identify and eliminate cancer cells. By inhibiting these critical effector T cells, IL-10-negative Tregs create an immune-suppressive environment conducive to tumor survival and expansion.
- Location: This harmful subtype of Treg cells was predominantly located within the tumor itself, strategically positioned to neutralize the immune response directly at the site of malignancy.
- Experimental Evidence: The selective elimination of IL-10-negative Treg cells in the mouse models resulted in a marked reduction in tumor size, confirming their detrimental role in promoting tumor growth by stifling the anti-cancer immune response.
Human Validation: Correlating Treg Subtypes with Patient Outcomes
To ensure the relevance of their findings to human disease, the research team meticulously validated their experimental results using tumor samples obtained from patients with colorectal cancer. In these human samples, they successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells, mirroring their observations in the mouse models.
Further strengthening their conclusions, the scientists analyzed clinical outcomes for over 100 colorectal cancer patients. The results were compelling: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer survival. Conversely, patients whose tumors were characterized by a greater abundance of the harmful IL-10-negative Treg cells experienced poorer outcomes. This direct correlation between Treg subtype prevalence and patient prognosis provides robust clinical validation for the mechanistic insights derived from the mouse models.
"This research shows how important these positive cells are," stated Dr. Huang. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment encapsulates the core clinical implication of the study: moving towards precision immunotherapies that fine-tune, rather than broadly modulate, the immune response.
A New Therapeutic Frontier: Targeting CCR8 for Selective Depletion
The findings from MSK suggest a highly promising new avenue for improving treatment strategies for the majority of colorectal cancer patients, particularly those with MSS/MMRp tumors who currently lack effective immunotherapy options.
The researchers made another critical discovery: the harmful IL-10-negative Treg cells express high levels of a specific protein called CCR8. Crucially, these CCR8-expressing cells are the very ones that actively suppress the anti-tumor immune response and are predominantly localized within the tumor microenvironment.
This finding builds upon earlier work from Dr. Rudensky’s lab, notably research led by breast cancer surgeon George Plitas, MD, which previously demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. That earlier research had already posited that antibodies designed to target CCR8 could serve as a highly selective mechanism to deplete these harmful Treg cells from tumors. The beauty of this approach lies in its potential to unleash the immune system’s attack on cancer more effectively, without compromising the beneficial Treg cells that maintain immune tolerance in healthy tissues.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky emphasized. Indeed, the concept has gained significant traction within the immuno-oncology field. Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously testing this innovative approach. These trials are evaluating CCR8-targeting antibodies both as monotherapy and in combination with existing immunotherapies, aiming to identify optimal treatment regimens. The new study on colorectal cancer significantly strengthens the rationale for deploying this strategy in CRC and expands its potential applicability across a broader spectrum of cancers.
Beyond Colorectal Cancer: Similar Immune Patterns in Other Barrier Tissues
Recognizing the potential for broader implications, the MSK team extended their analysis to a vast dataset of T cells derived from 16 different cancer types. This comprehensive examination aimed to determine whether the observed immune patterns, specifically the division between IL-10-positive and IL-10-negative Treg cells, were unique to colorectal cancer or manifested in other malignancies.
Their analysis revealed compelling evidence of similar divisions in several other cancers affecting "barrier tissues" – specifically, cancers of the skin and the linings of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explained Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This commonality suggests that the nuanced balance of Treg subtypes, reflecting the need for both immune defense and tolerance in these constantly challenged environments, might be a conserved immunological feature. Consequently, the researchers propose that therapeutic strategies designed to selectively remove IL-10-negative Treg cells, similar to the CCR8-targeting approach developed for colorectal cancer, might also prove effective against these other cancers arising in barrier tissues. This opens up the exciting possibility of a generalized precision immunotherapy platform.
The Complexity of Metastatic Disease: A Nuanced Immune Balance
The study also delved into the immune landscape of metastatic colorectal cancer, specifically examining tumors that had spread to the liver. Here, the researchers observed a distinctly different immune pattern compared to primary tumors.
In these metastatic sites, the harmful IL-10-negative Treg cells were found to vastly outnumber their beneficial IL-10-positive counterparts. This shift in the Treg balance at metastatic sites carries significant clinical implications. Unlike primary tumors, where selective targeting of IL-10-negative Tregs is paramount, the researchers found that removing all Treg cells in the context of liver metastases led to a shrinkage of these secondary tumors.
This critical finding underscores the profound importance of considering both the specific tissue involved and the stage of the disease when formulating treatment strategies. The immune microenvironment, and thus the optimal therapeutic approach, can vary significantly between a primary tumor and its metastases, even within the same patient. This highlights the need for a highly personalized and context-dependent approach to immunotherapy, moving beyond a "one-size-fits-all" paradigm.
Future Directions and the Promise of Precision Oncology
The findings from Memorial Sloan Kettering Cancer Center represent a significant leap forward in understanding the intricate interplay between the immune system and cancer. By resolving the long-standing paradox of Treg cells in colorectal cancer, the research team has not only provided a clear explanation for a confusing clinical observation but has also illuminated a promising path towards more effective and precise immunotherapies.
The shift in focus from merely counting Treg cells to discerning their distinct functional subtypes marks a paradigm shift in cancer immunology. It emphasizes the burgeoning field of precision oncology, where treatments are tailored to the specific molecular and immunological characteristics of an individual’s tumor. For the large population of colorectal cancer patients who currently do not benefit from existing immunotherapies, the selective targeting of harmful IL-10-negative Treg cells, particularly through approaches like CCR8-depleting antibodies, offers a beacon of hope. This approach aims to re-engineer the tumor microenvironment, tipping the scales in favor of the patient’s immune system, allowing it to effectively combat the cancer. The potential for these insights to extend to other difficult-to-treat cancers further amplifies the impact of this transformative research.
Authors, Funding, and Disclosures
Additional authors on the study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
The Integrated Genomics Operation and the Single Cell Research Initiative at MSK were instrumental in providing key technological support and expertise for this extensive research.
Funding for this pivotal study was generously provided by the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky serves on scientific advisory boards and holds equity in several biotechnology companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8. These disclosures highlight the potential for direct translation of this groundbreaking research into clinical applications, while maintaining transparency regarding potential conflicts of interest.
